Gleevec
information and resources from the National Cancer Institute
Gleevec
(Other name for: imatinib mesylate)Gliadel wafer
(Other name for: polifeprosan 20 with carmustine implant)Gleevec
(Other name for: imatinib mesylate)
imatinib mesylate
Accel. Approv. (clinical benefit not established) Initial therapy of chronic myelogenous leukemia
Novartis May 10 2001
imatinib mesylate
Accel. Approv. (clinical benefit not established) Initial treatment of newly diagnosed Ph+ chronic myelogenous leukemia (CML).
Novartis Dec 20 2002
imatinib mesylate
Accel. Approv. (clinical benefit not established) metastatic or unresectable malignant gastrointestinal stromal tumors
Novartis Feb 01 2002
|
|
|
|
news articles
MNP+, INP+ oppose patent for ARV drug 01 Apr 2006
KanglaOnline, Recently Indian cancer patients and generic drug manufacturers successfully opposed a Novartis patent application for Gleevec, an anti-cancer drug, on the ...
Gleevec Has Activity for Treatment of Aggressive Fibromatosis Mar 20, 2006
Cancer Consultants (press release), A multicenter trial has determined that Gleevec (imatinib) treatment of advanced aggressive fibromatosis (desmoid tumor) is associated with a 16% response rate ...
Surgery for Residual GIST May Improve Outcomes Mar 30, 2006
Cancer Consultants (press release), ...patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) that respond to treatment with Gleevec® (imatinib mesylate) may ...
A Stomach for Biotechs Mar 31, 2006
Smartmoney.com Novartis makes Gleevec, the first drug to fight cancer by turning off an enzyme that causes cells to become cancerous and multiply. ...
Activity Of Imatinib (Gleevec®) In Metastatic Renal Cell ... Mar 6, 2006
UroToday, BERKELEY, CA (UroToday.com) - Until recently, standard therapy for metastatic renal cell carcinoma (RCC) has been immunotherapy with either interleukin 2 or ...
Gleevec® Produces a Treatment Response in Some Patients with ... Mar 23, 2006
Cancer Consultants (press release), According to a phase II clinical trial published in the Journal of Clinical Oncology, treatment with Gleevec® (imatinib mesylate) reduced detectable disease ...
High-Dose Gleevec® and Low-Dose Chemotherapy Effective for ... Mar 17, 2006
Cancer Consultants (press release), According to an article recently published in the journal Leukemia, high doses of Gleevec® (imatinib mesylate) and low-dose chemotherapy appears to be an ...
High Dose Gleevec® and Low-Dose Chemotherapy Effective for ... Mar 17, 2006
Cancer Consultants (press release), Researchers from France have reported that high-dose Gleevec (imatinib) combined with vincristine and dexamethasone produced complete remissions (CR) in 28 of ...
SGX Pharmaceuticals Announces Strategic Collaboration to Develop ... Mar 29, 2006
Webbolt Business News, The success of Gleevec(TM) (imatinib), the first targeted therapy in Philadelphia Positive (Ph+CML) proven to inhibit BCR-ABL, has fundamentally changed the ...
For the First Time a Molecular Test Proves to be Effective in ... Mar 28, 2006
Hutchinson Center A Life of Science, ...use of a sensitive molecular test to measure the precise extent of remission or the likelihood of relapse in cancer patients being treated on Gleevec or a ...
SGX to collaborate on leukemia drug Mar 29, 2006
San Diego Union Tribune, ...$25 million up front from Novartis for collaborating on the development of a new drug for leukemia patients who become resistant to Gleevec, the standard ...
Highmark, UPMC team up to improve access to expensive cancer ... Mar 28, 2006
Pittsburgh Post Gazette, ...he can afford to keep living. The drug he takes, called Gleevec, costs about $40,000 per year. When he started taking the medication ...
SGX, Novartis Sign $515M Deal For CML Compounds Mar 28, 2006
BioWorld Online (subscription), ...drug-resistant chronic myelogenous leukemia and could provide an important alternative to patients who don’t respond to the current standard of care, Gleevec ...
SGX secures Novartis leukemia partnership Mar 29, 2006
Pharmaceutical Business Review Gleevec (imatinib), the blockbuster drug produced by Novartis, has been shown to help patients with this form of leukemia. However ...
Novartis May Pay SGX More Than $515 Million in Accord (Update3) Mar 28, 2006
Bloomberg ...more than $515 million to help develop leukemia drugs for use in patients who develop resistance to Gleevec, the Swiss drugmaker's second-biggest seller. ...
SGX Collaborates with Novartis to Develop and Commercialize BCR ... Mar 30, 2006
PharmacoGenomicsOnline.com (press release), The success of Gleevecâ„¢ (imatinib), the first targeted therapy in Philadelphia Positive (Ph+CML) proven to inhibit BCR-ABL, has fundamentally changed the ...
Contraception Remains Advisable with Imatinib Therapy Mar 30, 2006
Cancerpage.com, NEW YORK MAR 29, 2006 (Reuters Health) - While conception during treatment with imatinib (Gleevec) may result in normal pregnancies, an increased risk of ...
Island man victorious in fight for prescription coverage Mar 24, 2006
Hilton Head Island Packet, Hannah, 65, had battled for two months to regain coverage of the drug Gleevec, but he had lost three consecutive Medicare appeals. ...
SGX, Novartis Sign $515M Deal Mar 28, 2006
Red Herring, ...to develop are targeted at patients with chronic myelogenous leukemia (CML) who have developed resistance to drugs such as Novartis’s Gleevec, also known as ...
Activity Of Imatinib (Gleevec®) In Metastatic Renal Cell ... Mar 7, 2006
Medical News Today (press release), Until recently, standard therapy for metastatic renal cell carcinoma (RCC) has been immunotherapy with either interleukin 2 or interferon. ...
SGX, Novartis Sign $515M Deal For CML Compounds Mar 29, 2006
Therapeutics Daily (subscription) (press release), ...drug-resistant chronic myelogenous leukemia and could provide an important alternative to patients who don?t respond to the current standard of care, Gleevec. ...
SGX forges leukemia cancer deal with Novartis Mar 27, 2006
Reuters ...to develop drugs to treat chronic myelogenous leukemia that has become resistant to other treatments, including Novartis's own Gleevec, which targets the same ...
Novartis Payment For SGX License Looks High Mar 28, 2006
newratings.com 0927 GMT [Dow Jones]--Novartis (NVS) licenses SGX's (SGXP) BCR-ABL inhibitors against leukemia that is resistant to Novartis' Gleevec. ...
Britain: Breast cancer patient’s legal challenge highlights ... Mar 30, 2006
Asian Tribune, Other cancer-fighting drugs such as Avastin, Erbitux, Gleevec, Rituxan and Tarceva are also increasingly deemed too expensive and are not currently widely ...
Orphan Drug Designation Granted by the US FDA for Ceflatonin(R) Mar 19, 2006
Boursorama, ...demonstrated that Ceflatonin has potential in CML patients who are developing resistance to tyrosine kinase inhibitor (TKI) therapy, including Gleevec(R), and ...
FDA Orphan Drug Approvals: Ceflatonin, Valortim, TQ-1018 Mar 31, 2006
Medscape (subscription) ...effects in decreasing bcr-abl protein expression (the hallmark of CML resistance) when administered in combination with imatinib mesylate (Gleevec, made by ...
SGX Shares Leap on Deal With Novartis Mar 28, 2006
Forbes Novartis's blockbuster drug Gleevec has successfully inhibited in some patients the chromosomal abnormalities that cause chronic leukemia. ...
WSJ(3/28) Novartis, SGX Pair Up To Develop Leukemia Drugs Mar 28, 2006
Therapeutics Daily (subscription) (press release), ...a collaboration agreement to develop new drugs for patients with chronic myelogenous leukemia who develop resistance to Novartis's blockbuster treatment Gleevec ...
One man fights uphill battle to pay for prescription to treat rare ... Mar 5, 2006
Hilton Head Island Packet, To treat his disease, his doctors prescribed Gleevec, a drug that works by blocking the rapid growth of white blood cells. Hannah ...
New Therapies Target Cancer Mar 7, 2006
Drug Discovery & Development (subscription), In 2001, Gleevec (imatinib mesylate), made by Novartis AG, Basel, Switzerland, became the first approved kinase inhibitor for cancer, specifically chronic ...
That terrible Medicare hurricane Mar 17, 2006
Village News Network, But the VA plan limits drug choices, just like Canada’s system: though Gleevec is now considered first-line therapy for stomach cancer, the VA forces ...
Novartis Bulks Up Its Pipeline Mar 29, 2006
Motley Fool Novartis already has a stake in the ground here, since Gleevec is a BCR-ABL inhibitor, but drug resistance has proved to be a problem with some patients. ...
Coming Soon: Faster, Yet Still Safe, Clinical Trials Mar 29, 2006
Forbes That trial, which is still recruiting patients, will compare two doses of imatinib (Gleevec) against the experimental drug dasatinib, for patients with chronic ...
Medicare neglects rare diseases Mar 6, 2006
Beaufort Gazette, To treat Hannah's disease, his doctors prescribed Gleevec, a drug that works by blocking the rapid growth of white blood cells. ...
ChemGenex leukemia drug gets orphan nod Mar 20, 2006
United Press International ...potential treatment has shown promise in study patients who are becoming resistant to tyrosine kinase inhibitors -- including's Novartis' Gleevec -- as well as ...
Cancer Society works tirelessly to save lives Mar 21, 2006
News-Leader.com, ...billion on research, which has led to several advances, including the Pap test, the bone marrow transplant and drugs such as Tamoxifen and Gleevec, which have ...
Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy ... Mar 13, 2006
PR Newswire (press release), ...immunotherapy for leukemia in a Phase 2 clinical trial in patients with chronic myelogenous leukemia (CML) who have been treated with Gleevec(R) (imatinib ...
New Hope for Stomach Cancer Mar 1, 2006
ABC30.com, ...each year. For the past few years, Gleevec has been known as the wonder drug for these patients, but it can stop working. Now, researchers ...
Cell Genesys to Present Data From Two GVAX(R) Cancer Immunotherapy ... Mar 13, 2006
Yahoo! News (press release) ...for leukemia in a Phase 2 clinical trial in patients with chronic myelogenous leukemia (CML) who have been treated with Gleevec® (imatinib mesylate) for at ...
FDA Prioritizes Bristol Drug Mar 7, 2006
Red Herring, Many patients with chronic myeloid leukemia take Imatinib, also known as Gleevec, to treat the disease but later develop resistance to the drug. ...
BMS cancer drug gets FDA priority review Mar 7, 2006
United Press International ...is a second-generation protein tyrosine kinase inhibitor that some analysts predict could be as clinically and commercially successful as Novartis' Gleevec. ...
Novartis May Pay SGX More Than $515 Million in Accord (Update1) Mar 27, 2006
Bloomberg ...leukemia. Novartis now sells the Gleevec drug to fight this disease, but some patients develop resistance to the medicine. There ...
Long-Term Results of Stem Cell Transplants for CML Reported Mar 2, 2006
Cancer Consultants (press release), Prior to the development of Gleevec® (imatinib), allogeneic stem cell transplants were the treatment of choice for younger patients with CML. ...
United States-Republic of Korea Free Trade Agreement - CPTech ... Mar 27, 2006
Huffington Post, ...medicines, such as the case so eloquently examined in the film Dying for Drugs (copy mailed under separate cover), which examines the case of Gleevec in Korea ...
Playing Catch-up Mar 28, 2006
American Enterprise Institute, The biotech cancer drugs Gleevec and Avastin, for example, are already being used to treat cancers other than the ones for which they were originally approved. ...
American Journal of Respiratory and Critical Care Medicine Vol 173 ... Mar 28, 2006
AJRCCM (subscription), ...as leukotriene receptor antagonists do), but also prevent the production of leukotriene B 4 . The second study, of imatinib (Gleevec), suggested that it ...
Letter: Kennedy's deadly proposal Mar 14, 2006
MetroWest Daily News, For many important medicines, such as Gleevec for stomach cancer and mental illness medications, patients must "fail first" on a cheaper drug before they get a ...
The Fiercest Competition in Protein Kinase Inhibitors Drug ... Mar 8, 2006
Genetic Engineering News, The perfect date between Gleevec and Chronic Myeloid Leukemia (CML) will be hard to achieve by other inhibitors currently in development, because of CMLis ...
Join Relay for Life to help fight against cancer Mar 1, 2006
Polytechic Online, One result of this, for example, is that the drug Gleevec was recently developed to effectively battle a deadly form of leukemia. ...
Ambit Biosciences Adds Kinase Experts to Scientific Advisory Board ... Mar 7, 2006
PharmaLive.com (press release), ...in the discovery and development of kinase inhibitors to the Ambit team and is known for his discovery and preclinical development of Gleevec(TM), the ...
Adopt Knowledge from This Analysis to Drive Strategic Planning ... Mar 25, 2006
New Age Media Concepts (press release) Protein kinase inhibitors such as Gleevec, Iressa and Tarceva have allowed the biotechnology industry to deliver on the promise of targeted cancer drugs. ...
Careers in Cancer Research : Seeking Out the Source Mar 23, 2006
ScienceCareers.org, Some of the most recent include the discovery of stem-like cells related to cancer, target-specific drug therapy (Herceptin and Gleevec, for example), and the ...
Uncle Sam vets the names of potential drugs Mar 17, 2006
Pittsburgh Post Gazette, He says he urged Novartis AG to change the spelling and pronunciation for its high-profile cancer drug to Gleevec, after the FDA deemed Glivec too close to the ...
Path cleared for drug Mar 20, 2006
Geelong Advertiser, CML is one of the four most common types of leukemia. Ceflatonin was developed for patients who had developed a resistance to a previous drug called Gleevec. ...
Newly Discovered, Multitasking Killer Cells Fights Cancer Mar 20, 2006
Johns Hopkins Gazette, Zitvogel at the Institut Gustave Roussy, tested whether IKDCs are culprits in killing cancer by injecting mice with a cancer drug called Gleevec, which blocks ...
Cytomyx breaks mould Mar 21, 2006
Cambridge Evening News, New drugs such as Herceptin, a treatment for breast cancer, and Gleevec for the treatment of chronic myeloid leukaemia, have already demonstrated the value of ...
Research and Markets: The FDA is Encouraging the Use of Biomarkers ... Mar 22, 2006
PharmaLive.com (press release), ...diagnostics for molecularly targeted oncology drugs, including trastuzumab (Genentech's Herceptin), imatinib mesylate (Novartis's Gleevec), and cetuximab ...
Scotland team honours emotional Marsden Mar 13, 2006
Scotsman, ...history. "I took part in a clinical trial in 2001 for Gleevec and it's thanks to that that I'm here today," said Marsden. "It's ...
Irrepressible Marsden back again Mar 3, 2006
Scotsman, That determination was vindicated two years later, when treatment with a drug called Gleevec cured him of his potentially fatal condition. ...
New strategy developed to study disease: Reveals insights into ... Mar 9, 2006
Innovations-Report, ..."For example, Gleevec, which is used to treat gastrointestinal stromal tumors and chronic myeloid leukemia, is the most successful magic bullet against cancer ...
PRAECIS PHARMACEUTICALS INCORPORATED Presents Update on its ... Mar 15, 2006
Genetic Engineering News, ...of the DirectSelect(TM) libraries against three kinase and one protease target, including the cancer targets Aurora A kinase and Gleevec-resistant mutant Abl ...
Praecis Pharmaceuticals Presents Update On DirectSelect Drug ... Mar 15, 2006
Trading Markets, ...screening of the DirectSelect libraries against three kinase and one protease target, including the cancer targets Aurora A kinase and Gleevec-resistant mutant ...
Patients do their part in clinical trials Mar 16, 2006
Appleton Post Crescent, For instance, Beschta's study explores whether a drug called Gleevec, which already is FDA-approved for the treatment of some tumors, also can be used to ...
Blake MacDiarmid makes the rounds of political circles Mar 4, 2006
Boca Raton News, In 1998, they discovered a new drug in San Diego, Calif. It was called Gleevec – and “was one of the first truly targeted DNA drugs.�. ...
Pharma cos fight pitched battle on patent turf Mar 7, 2006
Hindu Business Line, Only recently, the Indian Patent office rejected Novartis's claim for a patent on imatinib mesylate, a cancer drug sold by it under the brand name Gleevec. ...
Novartis shareholders approve ninth consecutive higher dividend ... Feb 28, 2006
WebWire (press release), A program for Gleevec�/Glivec�, a leading targeted anti-cancer therapy for certain forms of leukemia and other tumors, has helped in 2005 more than 15,500 ...
Prescription Ills 21 Dec 2005
Modesto Bee, ...medicines. Gregory, who has Senior Advantage, said she paid $30 a month this year for Gleevec, a drug that she takes for leukemia. ...
Time In - Katie Knudson 21 Dec 2005
U.S. National Soccer Players, The doctors then discussed another option with the Knudsons - a new drug, "Gleevec" - that had been approved by the United States Food and Drug Administration ...
Silent Night, holy night, all is calm, all is bright… 21 Dec 2005
HoweStreet.com, Since a significant minority of CML patients—who initially responded well to the traditional drug Gleevec, which came out five years ago—have developed ...
Gleevec® plus Hydroxyurea Beneficial for Some Patients with ... Dec 20, 2005
Cancer Consultants (press release), According to a recent article published in the Journal of Clinical Oncology, the treatment combination consisting of Gleevec (imatinib mesylate) plus ...
AMN107 has potent activity in leukemia resistant to Gleevec Dec 13, 2005
PharmaLive.com (press release), ATLANTA - The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy ...
Gleevec Stops Leukemia Over Long Term Dec 14, 2005
Atlanta Journal Constitution (subscription), News) -- Nearly five years on, 90 percent of patients with a form of leukemia are alive and free of disease after taking the drug Gleevec (imatinib), according ...
More Than 90% of Patients Taking Gleevec(R) for a Form of Chronic ... Dec 12, 2005
Yahoo! News (press release) ...- For the first time, a separate retrospective comparison shows significant improvement in survival for Gleevec vs. historical interferon-based treatment. ...
More Than 90% of Patients Taking Gleevec(R) for a Form of Chronic ... Dec 12, 2005
PR Newswire (press release), ...less than 1% in the fourth year of treatment - For the first time, a separate retrospective comparison shows significant improvement in survival for Gleevec vs ...
More Than 90% of Patients Taking Gleevec for a Form of Chronic ... Dec 12, 2005
PharmaLive.com (press release), EAST HANOVER, NJ, December 12, 2005 /PRNewswire/ -- More than 90% of patients with a form of chronic myeloid leukemia (CML) who are taking Gleevec(R) (imatinib ...
CML Survival with Gleevec Remains High Dec 12, 2005
MedPage Today, 12 - More than 90% of patients taking Gleevec (imatinib mesylate) for chronic myeloid leukemia (CML) are alive and have not progressed to advanced disease more ...
Novartis Faces More Competition For Gleevec Dec 13, 2005
New Ratings 0821 GMT [Dow Jones]--Competition for Novartis' (NVS) second-best selling drug Gleevec is heating up with Bristol-Myers Squibb (BMY) presenting strong data on ...
AMN107 May Benefit Leukemia Patients Resistant to Gleevec ... Dec 12, 2005
DG News ATLANTA, GA -- December 12, 2005 -- The targeted agent AMN107 may be beneficial for some leukemia patients who are resistant to Gleevec (imatinib mesylate ...
Drug Could Augment or Replace Gleevec Dec 5, 2005
CancerWise An oral investigational drug, AMN107, is producing powerful responses for people resistant to Gleevec®, the medication that helps most chronic myeloid ...
Kepler: Mehr Wettbewerb für "Gleevec" von Novartis Dec 13, 2005
Tiscali, Drug works in patients who didn't respond to Gleevec. BMS plans to file drug by. end of '05 or early '06. On top of that, BMS is studying use of its own drug as ...
BMS' dasatinib expected to rival Gleevec Nov 21, 2005
Science Daily (press release) ...chronic myelogenous leukemia drug dasatinib, which is currently in phase 2 trials, could be as clinically and commercially successful as Novartis' Gleevec. ...
Results Encouraging with Interferon Alpha Plus Iressa (Gefitinib) ... Nov 22, 2005
DG News PHILADELPHIA, PA -- November 22, 2005 -- In a phase 2 study of interferon alpha (IFN) plus either Gleevec (imatinib mesylate) or Iressa (gefitinib) in patients ...
More Than 90% of Patients Taking Gleevec(R) for a Form of Chronic ... Dec 12, 2005
Finanzen.net, 12 /PRNewswire/ -- More than 90% of patients with a form of chronic myeloid leukemia (CML) who are taking Gleevec(R) (imatinib mesylate)* tablets in a landmark ...
It's Phase 3 for biotech CEO Dec 19, 2005
Bizjournals.com, ...ran Novartis' North American oncology operations and helped engineer domestic launches of a number of drugs, including the cancer treatment Gleevec in 2001 ...
Two-pronged strategy launches assault on blood cancer Dec 14, 2005
Asbury Park Press, Doctors and patients around the world hailed the approval of Gleevec in 2001, which revolutionized the treatment of chronic myeloid leukemia and marked the ...
Backyard Garden May Yield Leukemia Treatment Dec 9, 2005
Science Daily (press release) Gene-Silencing Technique Offers New Way To Fight Drug-Resistant Leukemia (November 4, 2004) -- Ever since the approval of Gleevec in 2001, a cancer-cell ...
Cell Genesys Reports Positive Results From Phase 2 Trial of GVAX(R ... Dec 12, 2005
PR Newswire (press release), Vaccine Reduces Molecular Evidence of Persistent Leukemia After Long-Term Gleevec(R) Therapy ATLANTA, Dec. 12 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. ...
ChemGenex Reports Compelling Phase 2 Data Published In Leading ... Dec 11, 2005
PR Newswire (press release), 100% Response Rate in Gleevec(R)-Resistant CML Patients MELBOURNE, Australia and MENLO PARK, Calif., Dec. 11 /PRNewswire- FirstCall ...
Cell Genesys Reports Positive Results From Phase 2 Trial of GVAX(R ... Dec 12, 2005
PharmaLive.com (press release), Nineteen CML patients with molecular evidence of persistent leukemia despite more than one year of Gleevec(R) (imatinib mesylate) therapy were treated with ...
Common garden plant may hold cure for leukemia Dec 12, 2005
News-Medical.net, ...expected to develop CML this year, in particular those in the advanced stages of the disease, or those who become resistant to the commonly used drug Gleevec. ...
Researchers Closer to Understanding How One Mutation Causes Three ... Dec 19, 2005
Howard Hughes Medical Institute, ...their findings will help them develop targeted drug therapies for the three disorders, similar to what has already been achieved for CML with the drug Gleevec. ...
ChemGenex Reports Compelling Phase 2 Data Published In Leading ... Dec 11, 2005
Yahoo! News (press release) One small Phase 2 study delivered HHT subcutaneously to late chronic stage CML patients with resistance to Gleevec®(1). All five evaluable patients achieved a ...
SGX Pharmaceuticals Presenting Data at American Society of ... Dec 13, 2005
Yahoo! News (press release) Meeting and Exposition showing that compounds discovered by applying its FAST(TM) lead discovery platform potently inhibit wild-type and Gleevec-resistant BCR ...
US launches cancer gene mapping project Dec 13, 2005
Reuters ...the successes of a few targeted cancer therapies such as Genentech Inc's Herceptin, useful against one type of breast cancer, and Novartis' Gleevec, a pill ...
Novartis Abandons Development of Cholesterol Drug (Update2) Dec 16, 2005
Bloomberg The company has introduced 14 products in the US since 2000, more than any rival of comparable size, with only cancer medicines Zometa and Gleevec bringing in ...
Novartis Abandons Development of Cholesterol Drug (Update1) Dec 15, 2005
Bloomberg While Novartis has introduced 14 products in the US since 2000, more than any rival of comparable size, only cancer medicines Zometa and Gleevec bring in more ...
Gene mapping project promises new targeted cancer therapies Dec 14, 2005
News-Medical.net, ...enable them to replicate the successes of the few targeted cancer therapies such as Herceptin, useful against one type of breast cancer, and Gleevec, a drug ...
AMN107 can produce benefits in patients with some forms of ... Dec 12, 2005
Xagena.it, Cancer Center found that AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Imatinib ( Gleevec/Glivec ), the ...
Bristol-Myers' Cancer Drug May Benefit Patients, Study Shows Dec 10, 2005
Bloomberg Bloomberg) -- Bristol-Myers Squibb Co.'s experimental cancer drug, dasatinib, appears to work in leukemia patients who are resistant to Novartis AG's Gleevec. ...
New drug fights leukaemia Dec 12, 2005
Health24.com, A new compound shows promise in patients with forms of leukaemia that resist the powers of Gleevec, Texas researchers report. The ...
ASH Data Continue Building Dec 12, 2005
TheStreet.com One of the key announcements concerned Gleevec, the drug from Swiss pharmaceuticals company Novartis (NVS:NYSE ADR - commentary - research - Cramer's Take ...
Glivec Seeking to Become First Targeted Treatment for Adult ... Dec 13, 2005
PharmaLive.com (press release), Switzerland, December 13, 2005 – Novartis has submitted a marketing authorization application for Glivec® (imatinib) Known as Gleevec® (imatinib mesylate ...
HEALTH: Experts to create genetic map of cancer Dec 18, 2005
Daily Times, A handful of so-called targeted drugs — Herceptin, Gleevec, Iressa, Tarceva — are proving remarkably effective at battling certain cancers in patients with ...
Surprise benefit of unexpected diagnosis Nov 23, 2005
CNN ...on an article about young women diagnosed with CML who were experiencing remarkable remissions through treatment with the cancer pill Gleevec (imatinib mesylate ...
Plant extract forskolin may lead to leukemia treatment Nov 20, 2005
News-Medical.net, ...in the United States who are expected to develop CML this year - especially those with advanced disease, or those who become resistant to the drug Gleevec. ...
Novartis files for European approval for Glivec in Ph+ ALL ... Dec 12, 2005
Forbes Submission for approval in the US, where the drug is known as Gleevec, is planned to occur by the end of 2005, the Swiss drugmaker said. ...
Cell Genesys says Phase 2 trail for leukemia vaccine positive Dec 12, 2005
Reuters In a statement, the company said the initial findings of this trial indicated that the addition of the vaccine to Gleevec therapy has reduced persistent ...
Novel Drug Shows Strong Efficacy in Imatinib-Resistant Leukemia Dec 13, 2005
Cancerpage.com, NEW YORK DEC 12, 2005 (Reuters Health) -- A new drug in phase I/II trials is safe and effective in treating imatinib (Gleevec/Glivec)-resistant chronic myeloid ...
Cell Genesys Posts Positive Study Data Dec 12, 2005
MSN Money ...patients in the nine-week study had chronic myelogenous leukemia whose disease had persisted despite more than one year on another drug, Novartis AG's Gleevec. ...
Novartis to pay Astex to $520 m for drug rights Dec 6, 2005
Financial Express, Novartis, Europe’s second-largest drugmaker by market value, already sells oncology drugs including Gleevec and Zometa, both of which brought in more than $1 ...
HEALTH BRIEFS Dec 5, 2005
Fort Worth Star Telegram, Promising new research finds that the leukemia drug Gleevec -- imatinib mesylate -- could one day help shield people from smallpox, a virus that experts fear ...
Chronic leukemias: different forms, different problems, different ... Nov 18, 2005
Pharmaceutical Business Review The treatment of CML was transformed with the US launch of Novartis' Gleevec in December 2002. Gleevec's unequivocal efficacy, coupled ...
Through charities, drug makers help people Dec 1, 2005
Pittsburgh Post Gazette, ...pocket costs. Vivian Gushwa, 70, was prescribed the cancer drug Gleevec after her rare gastrointestinal tumor recurred last year. Her ...
Chronic Leukemias - Curative Intent Raises the Bar Nov 22, 2005
Genetic Engineering News, The emergence of Gleevec-resistant CML, reported at rates of 4% with each year of treatment, coupled with only a 50% response rate in patients with advanced ...
US to create map of cancer genome Dec 13, 2005
CBC Nova Scotia, ...has allowed researchers to develop the first drugs that target specific faulty genes, such as Herceptin for one form of breast cancer and Gleevec for chronic ...
New Effort Aims to Unlock Secrets of Cancer Genes Dec 13, 2005
New York Times, The drug Gleevec, which blocks a particular genetic change that causes a type of leukemia, produces remissions in most patients with that form of the disease. ...
Cancer genome project likely to benefit Houston Dec 13, 2005
Houston Chronicle, ...effects of chemotherapy. Two of the best known are Gleevec, for chronic myeloid leukemia, and Herceptin, for breast cancer. Now that ...
Novartis Abandons Development of Cholesterol Drug (Update4) Dec 16, 2005
Bloomberg Novartis has introduced 14 products in the US since 2000, more than any rival of comparable size, but only cancer medicines Zometa and Gleevec generated more ...
UNLOCKING CANCER GENES Dec 14, 2005
PBS We basically believe that this fruitful concept we've seen through the treatment of diseases like chronic myologic leukemia with Gleevec and Herceptin and ...
Source: Quest Diagnostics Incorporated Dec 9, 2005
Yahoo! News (press release) The study showed that plasma-based testing assessed mutations associated with resistance to therapy, in this case Gleevec (Imatinib). ...
Hana Biosciences Announces Changes to Strengthen Management Team Dec 16, 2005
Business Wire (press release), While on the faculty at Cornell, Dr. Berk was an investigator in numerous clinical trials, including the Gleevec pivotal trials, Avastin colorectal and breast ...
Scientists map cell signaling network Dec 1, 2005
myDNA.com, Although protein kinases are already important targets of cancer drugs such as Gleevec and Herceptin, until recently, it has been difficult to identify the ...
New Therapy For Prostate Cancer Survivors Dec 1, 2005
13WHAM-TV, First, after at least three tests show they have rising PSA levels, the subjects spend six months taking a chemo drug and Gleevec, a new medication recently ... |
